Tissue Regenix Share Discussion Threads

[bamboo2] 11/2/2015 08:20

bobs, the healing rates for those with chronic conditions lasting less than 12-18 months seem excellent. It would be very interesting to know if those very long term patients without complete healing from one treatment could see a benefit from a second application.

[bobsgonnamakemerich] 10/2/2015 23:48

hxxp://www.nhsbt.nhs.uk/tissueservices/pdf/products/productsheet/human_dermis.pdf

A good read for any newcomers interested in the product. Note 100% heal on diabetic ulcers (granted a sample size of 3 is not going to be conclusive but I will claim it anyway!)

[bamboo2] 10/2/2015 19:05

bobs, yes we have a virtual monopoly.

The barriers to entry are huge, if not insurmountable for the supply of UK derived human based ECM's, because only our partner, nhsbt can provide the material for processing.

[bobsgonnamakemerich] 10/2/2015 18:58

I thought i was going mad, then I realised this is us.

[bamboo2] 10/2/2015 18:07

Hi Ig, Well found! This is just the kind of advertising we need to help increase the number of patient led enquiries for dCell Dermis.
Ardy Bayat has been on the frontline, flying the flag for our products for a long while and it's great to see him get some popular recognition.

[igbertsponk] 10/2/2015 16:57

Competition ?

[loldemort] 07/2/2015 06:08

"The trial involves a National Health Service Blood and Transplant (Watford, UK) derived product that has been licensed to Tissue Regenix."

I hadn't picked up on that. I had thought all our IP was based on University of Leeds stuff. I knew we were supplying to NHSBT but I didn't realise it was also the other way around.

Hmm, the site company *does* say "The company commercialises academic research conducted by our partners around the World", so perhaps I'm getting nervous about nothing. Just a bit jittery about this current market.

[bamboo2] 04/2/2015 23:20

Thanks luminoso

==========================

A trx part-funded study into angiogenesis, this is the growth and formation of a new blood supply into, for example, an ECM. This kind of research is important because it provides evidence of the differences between the way our product performs when compared with others.



=========================

04/02/2015 Notice of allowance received for meniscus patent in Canada

=========================

Documentation for Meniscus trial. 17/10/2014

[luminoso] 03/2/2015 10:29

Of general interest, maybe. Courtesy of someuwin on SUMM board :-

"Investment magnate Jim Mellon is looking to raise up to £100m for an investment trust targeting biotechnology companies working at the cutting-edge of medical science.

The trust, planned for launch in March or April, will trade in small biotech firms including unquoted shares, of the type that have found favour with investing heavyweights such as Neil Woodford.

It will be managed by former Axa Framlington Biotechnology fund manager Andy Smith, who is chief investment officer at Mr Mellon’s fledgling specialist investment house Mann Biovest.

Outlining hopes for a fundraising of £50-£100m, expected to be led by broker firm Investec, Mr Mellon said: “There is nothing in the UK like this.

“It is going to invest purely in small biotech companies in the UK and Europe.”

The launch brings Mr Mellon, who made a fortune investing in emerging markets in the 1990s, squarely up against his rich-list rival Mr Woodford, who also plans to launch an investment trust imminently, investing partly in biotechnology.

He added that he welcomed the launch of a rival fund by Mr Woodford, which will draw even more attention to what he views as an underinvested industry.

Biotechnology is rising in popularity as an investment in the UK.

Proponents of the sector argue that the sequencing of the human genome has led to a golden age in the discovery of breakthrough new drugs. At the same time, they argue, the world’s aging population is creating a greater demand than ever for disease treatments.

The US has long had a major biotechnology sector but in the UK there is now a slew of micro-sized companies, many of which have been spun out of university research at Oxford and Cambridge.

Mr Smith and Mann Biovest already act as investment manager to Magna Biopharma Income, a Charlemagne Capital open-ended fund that targets much larger-sized pharmaceutical companies with a higher level of liquidity.

The fund was launched in December 2013 and since then its sterling share class has delivered a 28.1 per cent return compared to a return on the MSCI World Healthcare index of 36.6 per cent in sterling terms.

Isle of Man-based Mann Biovest was launched in 2012 and its founder Mr Mellon acts as chairman and advisory committee member. The group’s chief executive is Anthony Chow, a former analyst at ANZ Banking Group in Sydney.

Before working at Axa Investment Managers, Mr Smith previously ran the International Biotechnology Trust and the Bioscience Investment trust, two of the UK’s highest profile funds in the sector."

hxxp://www.ftadviser.com/2015/02/02/investments/alternative-investments/mellon-s-new-trust-to-target-biotech-firms-8PsKATWHgjxhm78WZJ66yN/article.html

[bamboo2] 01/2/2015 16:53

bobs, I seem to remember from the last CPM day that there was an issue with dealing with the EU. It seems each country has its own particular health system, with most requiring dealing with at individual hospital level. My guess is that the products will become familiar in the US and UK first then trade on their reputation elsewhere in the world. There were moves to start marketing in a few of the more straight forward countries.

The UK does have centralised purchasing in the form of our partner NHSBT, however, the commercial nature of the relationship seems to have been kept under wraps for now. Again just a guess, I think initially there has been a swap of information, or a mutual back-scratching going on, with NHSBT allowing access to research material and data sharing. This chimes with Eileen Inghams principal goal of wanting to help patients.

The new boss [Ian Trenholm] at NHSBT has recognised that there is a problem in the slower than forecast take up dCell Dermis, and is actively addressing various interest groups at the moment. Presumably this will include looking at the arrangement with the company.

Re the CE mark, I think this is already in place for dermis and a number of other products and it is a requirement for all medical devices before they can be marketed.

[bobsgonnamakemerich] 01/2/2015 14:44

Just read through it all again bb2. Yes sounds like things are moving forward nicely with dermapure, seems 7 sales reps are not enough!

I still can't get my head around timescales for commercialising human dermis in EU (and UK), there is a note on getting CE mark but that is in relation to Porcine, nothing in the development graphic either.

[bamboo2] 01/2/2015 13:49

"....encouraging momentum since the launch of DermaPure® in the US, with initial revenues now being recognised as anticipated.

Near term objectives for 2015 include line extensions in the dental and orthopaedic markets in order to expand the commercial opportunity for DermaPure®, which will pave the way for launch in other orthopaedic applications. In addition, the Company aims to launch SurgiPure® in the US, the porcine general surgical patch, complete the clinical results from the EU trial of the porcine meniscus product and complete the relocation of the UK manufacturing facility."

[bamboo2] 30/1/2015 17:16

Project Titan anyone? This is a co PDF issued at the time of the placing. I'm not sure about the reason for the Titan reference.

[bamboo2] 30/1/2015 16:27

Ray, here we go, new vid on the US site.

DermaPure® Application Video.

[bamboo2] 29/1/2015 18:48

Yes Ray. This is the calm before the storm. :o)
Loads of news to get our teeth into, but not until later in the year!

[rayrac] 29/1/2015 17:52

My usual comment. Is there anyone there? Apart from me, of course!😰

[bobsgonnamakemerich] 23/1/2015 18:18

Holding RNS's will be interesting to see who has bought the 30m shares today. I hope it's Woodford.

[grahamburn] 23/1/2015 17:51

bamboo2.

Pleased to see that you state what I said to myself yesterday morning (but didn't post).

Though the successful placing is positive news in the medium term, it is also firm evidence that revenues are being pushed out by some months and are going to be harder to come by than first thought. I had originally anticipated positive inflows late in 2015, but these now look like they may well be a year or so later and will be much more expensive to secure.

On the positive side the emphasis on other products evident in the placing announcement does mean that the company is determined to add more strings to its bow.

So, in general terms, the placing is good news - though you could well be right that the few large sells today are existing major holders banking some profits, while keeping the same money in the game.

[rafboy] 23/1/2015 16:04

Lets hope so; however, 10 Feb is a bit away yet.

[bamboo2] 23/1/2015 15:54

Ig, the shares in the placing are not admitted to the market until 10 February. It could though be the case that participants in the placing who are already holders are selling existing holdings.

The placing is an admission from the co that commerciality will take longer than expected. The sales could be a reflection of this fact.

raf, I think the placing has put a floor in, for now at least.

[rafboy] 23/1/2015 15:20

You would think the placing price would put a floor under the share price

[igbertsponk] 23/1/2015 15:12

Shares traded will be the placing

[rayrac] 23/1/2015 15:04

46m shares traded! Isn't that a bit unusual?

Wish I were a fly....

[rayrac] 23/1/2015 13:03

That's what happens when dealing with short term 'traders' ie, institutions!

Cheap and nasty.😜